This announcement is a separate document:
杭州天目山药业股份有限公司关于收到上海证券交易所《关于公司2023年年度报告信息披露问询函》的公告
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on receiving the Shanghai Stock Exchange's “Inquiry Letter on the Company's 2023 Annual Report Information Disclosure”
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.